Literature DB >> 24886838

Secondary prevention trials in Alzheimer disease: the challenge of identifying a meaningful end point.

Richard J Kryscio1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24886838      PMCID： PMC4375727          DOI： 10.1001/jamaneurol.2014.1120

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN： 2168-6149            Impact factor:   18.302


× No keyword cloud information.
  10 in total

1.  The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes.

Authors:  Laurel A Beckett; Danielle J Harvey; Anthony Gamst; Michael Donohue; John Kornak; Hao Zhang; Julie H Kuo
Journal:  Alzheimers Dement       Date:  2010-05       Impact factor: 21.566

2.  Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI).

Authors:  Paul K Crane; Adam Carle; Laura E Gibbons; Philip Insel; R Scott Mackin; Alden Gross; Richard N Jones; Shubhabrata Mukherjee; S McKay Curtis; Danielle Harvey; Michael Weiner; Dan Mungas
Journal:  Brain Imaging Behav       Date:  2012-12       Impact factor: 3.978

3.  Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials.

Authors:  Lon S Schneider; Richard E Kennedy; Gary R Cutter
Journal:  Alzheimers Dement       Date:  2010-09       Impact factor: 21.566

Review 4.  Can we prevent Alzheimer's disease? Secondary "prevention" trials in Alzheimer's disease.

Authors:  Maria C Carrillo; H Robert Brashear; Veronika Logovinsky; J Michael Ryan; Howard H Feldman; Eric R Siemers; Susan Abushakra; Dean M Hartley; Ronald C Petersen; Ara S Khachaturian; Reisa A Sperling
Journal:  Alzheimers Dement       Date:  2013-02-12       Impact factor: 21.566

Review 5.  Power calculations for clinical trials in Alzheimer's disease.

Authors:  M Colin Ard; Steven D Edland
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

6.  Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's disease.

Authors:  Ellen Grober; Charles B Hall; Richard B Lipton; Alan B Zonderman; Susan M Resnick; Claudia Kawas
Journal:  J Int Neuropsychol Soc       Date:  2008-03       Impact factor: 2.892

7.  Combining Multiple Markers to Improve the Longitudinal Rate of Progression-Application to Clinical Trials on the Early Stage of Alzheimer's Disease.

Authors:  Chengjie Xiong; Gerald van Belle; Kewei Chen; Lili Tian; Jingqin Luo; Feng Gao; Yan Yan; Ling Chen; John C Morris; Paul Crane
Journal:  Stat Biopharm Res       Date:  2013-01-01       Impact factor: 1.452

8.  Designing a large prevention trial: statistical issues.

Authors:  Richard J Kryscio; Marta S Mendiondo; Frederick A Schmitt; William R Markesbery
Journal:  Stat Med       Date:  2004-01-30       Impact factor: 2.373

Review 9.  Clinical trials in predementia stages of Alzheimer disease.

Authors:  Jagan A Pillai; Jeffrey L Cummings
Journal:  Med Clin North Am       Date:  2013-02-22       Impact factor: 5.456

10.  The preclinical Alzheimer cognitive composite: measuring amyloid-related decline.

Authors:  Michael C Donohue; Reisa A Sperling; David P Salmon; Dorene M Rentz; Rema Raman; Ronald G Thomas; Michael Weiner; Paul S Aisen
Journal:  JAMA Neurol       Date:  2014-08       Impact factor: 18.302
  10 in total
  12 in total

1.  Association of Antioxidant Supplement Use and Dementia in the Prevention of Alzheimer's Disease by Vitamin E and Selenium Trial (PREADViSE).

Authors:  Richard J Kryscio; Erin L Abner; Allison Caban-Holt; Mark Lovell; Phyllis Goodman; Amy K Darke; Monica Yee; John Crowley; Frederick A Schmitt
Journal:  JAMA Neurol       Date:  2017-05-01       Impact factor: 18.302

2.  Prevention studies in Alzheimer's disease: progress towards the development of new therapeutics.

Authors:  Nicola Coley; Adeline Gallini; Sandrine Andrieu
Journal:  CNS Drugs       Date:  2015-07       Impact factor: 5.749

3.  Risk of dementia and death in the long-term follow-up of the Pittsburgh Cardiovascular Health Study-Cognition Study.

Authors:  Lewis H Kuller; Oscar L Lopez; James T Becker; Yuefang Chang; Anne B Newman
Journal:  Alzheimers Dement       Date:  2015-10-28       Impact factor: 21.566

4.  Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease.

Authors:  Emily C Edmonds; Lisa Delano-Wood; Douglas R Galasko; David P Salmon; Mark W Bondi
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

Review 5.  Metabolic and Non-Cognitive Manifestations of Alzheimer's Disease: The Hypothalamus as Both Culprit and Target of Pathology.

Authors:  Makoto Ishii; Costantino Iadecola
Journal:  Cell Metab       Date:  2015-09-10       Impact factor: 27.287

6.  Before it is too late: professional responsibilities in late-onset Alzheimer's research and pre-symptomatic prediction.

Authors:  Silke Schicktanz; Mark Schweda; Jesse F Ballenger; Patrick J Fox; Jodi Halpern; Joel H Kramer; Guy Micco; Stephen G Post; Charis Thompson; Robert T Knight; William J Jagust
Journal:  Front Hum Neurosci       Date:  2014-11-20       Impact factor: 3.169

7.  Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Z-scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score.

Authors:  Yen Ying Lim; Peter J Snyder; Robert H Pietrzak; Albulene Ukiqi; Victor L Villemagne; David Ames; Olivier Salvado; Pierrick Bourgeat; Ralph N Martins; Colin L Masters; Christopher C Rowe; Paul Maruff
Journal:  Alzheimers Dement (Amst)       Date:  2015-12-12

8.  Aerobic exercise for Alzheimer's disease: A randomized controlled pilot trial.

Authors:  Jill K Morris; Eric D Vidoni; David K Johnson; Angela Van Sciver; Jonathan D Mahnken; Robyn A Honea; Heather M Wilkins; William M Brooks; Sandra A Billinger; Russell H Swerdlow; Jeffrey M Burns
Journal:  PLoS One       Date:  2017-02-10       Impact factor: 3.240

9.  Composite cognitive and functional measures for early stage Alzheimer's disease trials.

Authors:  Lon S Schneider; Terry E Goldberg
Journal:  Alzheimers Dement (Amst)       Date:  2020-05-15

10.  Dose-Response of Aerobic Exercise on Cognition: A Community-Based, Pilot Randomized Controlled Trial.

Authors:  Eric D Vidoni; David K Johnson; Jill K Morris; Angela Van Sciver; Colby S Greer; Sandra A Billinger; Joseph E Donnelly; Jeffrey M Burns
Journal:  PLoS One       Date:  2015-07-09       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.